tert-butyl N-(tert-butoxycarbonyl)-S-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-L-cysteinyl-L-phenylalaninate | 1138243-06-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-(tert-butoxycarbonyl)-S-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-L-cysteinyl-L-phenylalaninate
• CAS: 1138243-06-7
• 化学式: C₂₇H₄₃ClN₂O₇S
• 分子量: 575.167
• InChiKey: NRNQDLDKWBGKAM-VXKWHMMOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.95
• 重原子数：
  38.0
• 可旋转键数：
  16.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  112.19
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  Boc-Cys-Ile-Phe-NH2 、 tert-butyl N-(tert-butoxycarbonyl)-S-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-L-cysteinyl-L-phenylalaninate 在 苄基三乙基氯化铵 、 potassium carbonate 、 sodium bromide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以52%的产率得到tert-butyl ((6R,19R)-6-(((2S,3S)-1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)carbamoyl)-19-((tert-butoxycarbonyl)amino)-2,2-dimethyl-4-oxo-3,11,14-trioxa-8,17-dithia-5-azaicosan-20-oyl)-L-phenylalaninate
  参考文献：
  名称：

  Sidechain-linked inhibitors of HIV-1 protease dimerization

  摘要：

  There is a great need for alternative modes of inhibition for the design of anti-HIV therapies, due to the increased resistance of HIV to currently approved drugs. A novel strategy for generating potent dimerization inhibitors of HIV-1 protease is described based on sidechain-linked interfacial peptides. In a number of cases the activity of these agents against HIV-1 protease was found to be among the most potent reported, with inhibitory constants in the low nM range. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.060
• 作为产物：
  描述：

  Boc-Cys-Phe-O-tBu 、 1,2-二(2-氯乙氧基)乙烷 在 苄基三乙基氯化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以84%的产率得到tert-butyl N-(tert-butoxycarbonyl)-S-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-L-cysteinyl-L-phenylalaninate
  参考文献：
  名称：

  Sidechain-linked inhibitors of HIV-1 protease dimerization

  摘要：

  There is a great need for alternative modes of inhibition for the design of anti-HIV therapies, due to the increased resistance of HIV to currently approved drugs. A novel strategy for generating potent dimerization inhibitors of HIV-1 protease is described based on sidechain-linked interfacial peptides. In a number of cases the activity of these agents against HIV-1 protease was found to be among the most potent reported, with inhibitory constants in the low nM range. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.060